BioAtla (BCAB) Change in Interest Receivables (2020 - 2021)
BioAtla's (BCAB) quarterly Change in Interest Receivables came in at -$2000.0 in Q2 2021, up 99.83% year-on-year from -$1000.8 in Q2 2020, and down 100.0% quarter-over-quarter from -$1000.0 in Q1 2021.
BioAtla (BCAB) Change in Interest Receivables (2020 - 2021) Analysis & Trends
BioAtla's Change in Interest Receivables history runs 2 years deep, the most recent figure standing at -$2000.0 for Q2 2021.
- On a quarterly basis, Change in Interest Receivables rose 99.83% year-over-year to -$2000.0 in Q2 2021; TTM through Mar 2022 was -$2000.0, a 99.84% increase from a year earlier, with the FY2021 full-year figure at -$3000.0, up 99.65% from the prior year.
- Change in Interest Receivables retreated to -$2000.0 in Q2 2021 per BCAB's latest filing, from -$1000.0 in the prior quarter.
- Across five years, Change in Interest Receivables topped out at $379000.0 in Q1 2020 and bottomed at -$1.2 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Interest Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | BioAtla | 5.74 Mn | 5.74 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -2,000.00 |
| Mar 31, 2021 | -1,000.00 |
| Dec 31, 2020 | -2,000.00 |
| Sep 30, 2020 | -49,000.00 |
| Jun 30, 2020 | -1.19 Mn |
| Mar 31, 2020 | 379,000.00 |